Salicylate derivatives and related anti-inflammatory drugs such as diflunisal have also been demonstrated to inhibit both CBP and p300 and shown anti-leukemic activity in pre-clinical AML models38. The gene discussed is CREBBP; the disease is acute myeloid leukemia.